Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups

Extremity rhabdomyosarcomas do not always show satisfactory outcomes. We analyzed data from 643 patients treated in 14 studies conducted by European and North American groups between 1983 and 2004 to identify factors predictive of outcome.

[1]  M. Stevens,et al.  Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  F. Barr,et al.  Classification of Rhabdomyosarcoma and Its Molecular Basis , 2013, Advances in anatomic pathology.

[3]  P. Minneci,et al.  Sentinel lymph node biopsy in pediatric soft tissue sarcoma patients: utility and concordance with imaging. , 2013, Journal of pediatric surgery.

[4]  Sara M. Federico,et al.  Comparison of PET–CT and conventional imaging in staging pediatric rhabdomyosarcoma , 2013, Pediatric blood & cancer.

[5]  M. Stevens,et al.  Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Carli,et al.  Long‐term results in childhood rhabdomyosarcoma: A report from the Italian cooperative study RMS 79 , 2012, Pediatric blood & cancer.

[7]  James R. Anderson,et al.  Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: a report from the Children's Oncology Group. , 2011, International journal of radiation oncology, biology, physics.

[8]  James R. Anderson,et al.  Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: Combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumor , 2011, International journal of cancer.

[9]  O. Delattre,et al.  Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Pappo,et al.  Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in‐transit lymphatic system at risk? , 2009, Pediatric blood & cancer.

[11]  James R. Anderson,et al.  Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Schmelzle,et al.  Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. , 2009, Journal of Clinical Oncology.

[13]  James R. Anderson,et al.  Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Winkler,et al.  Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  James R. Anderson,et al.  Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Postovsky,et al.  Assessing the Use of FDG-PET in the Detection of Regional and Metastatic Nodes in Alveolar Rhabdomyosarcoma of Extremities , 2006, Journal of pediatric hematology/oncology.

[17]  H. B. Marsden,et al.  Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Stevens.  Treatment for childhood rhabdomyosarcoma: the cost of cure. , 2005, The Lancet. Oncology.

[19]  James R. Anderson,et al.  Age is an independent prognostic factor in rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children's oncology group , 2004, Pediatric blood & cancer.

[20]  J. Meza,et al.  Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG. , 2001, International journal of radiation oncology, biology, physics.

[21]  James R. Anderson,et al.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Stevens,et al.  Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment--results of an international workshop. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E. Wiener,et al.  Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). , 2000, Journal of pediatric surgery.

[24]  G. Henze,et al.  Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Voûte,et al.  Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. , 1998, European journal of cancer.

[26]  M. Carli,et al.  Summary of the International Symposium on Childhood Non-Rhabdomyosarcoma Soft-Tissue Sarcomas, Padua, Italy, February 10-12, 1994. , 1996, Medical and pediatric oncology.

[27]  E. Gehan,et al.  The Third Intergroup Rhabdomyosarcoma Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Jürgens,et al.  Treatment of soft tissue sarcoma in childhood and adolescence: A report of the german cooperative soft tissue sarcoma study , 1992, Cancer.

[29]  A. Auquier,et al.  Prognostic factors in 951 nonmetastatic rhabdomyosarcoma in children: a report from the International Rhabdomyosarcoma Workshop. , 1991, Medical and pediatric oncology.

[30]  D. Penenberg,et al.  Factors predictive of mortality in pediatric extremity rhabdomyosarcoma. , 1990, Journal of pediatric surgery.